                         SEQUENCE LISTING

<110>  Dignify Therapeutics
 
<120>  COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION

<130>  336/11 PCT

<150>  US 63/089,268
<151>  2020-10-08

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Met-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Met at position 6 has a NH2 group at the carboxyl terminus

<400>  1

Xaa Asp Ser Phe Val Met 
1               5       


<210>  2
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Nle-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is Nle with a NH2 group at the carboxy terminus

<400>  2

Xaa Asp Ser Phe Val Xaa 
1               5       


<210>  3
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Met-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Met at position 6 has a NH2 group at the carboxy terminus

<400>  3

Xaa Asp Lys Phe Val Met 
1               5       


<210>  4
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Nle-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is Nle that has a NH2 group at the carboxy 
       terminus

<400>  4

Xaa Asp Lys Phe Val Xaa 
1               5       


<210>  5
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Met-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Met at position 6 has a NH2 group at the carboxy terminus

<400>  5

Xaa Asp Arg Phe Val Met 
1               5       


<210>  6
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is absent

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Nle-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is Nle with a NH2 group at the carboxy terminus

<400>  6

Xaa Asp Arg Phe Val Xaa 
1               5       


<210>  7
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Nle-NH2 at position 6

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is Nle with a NH2 group at the carboxy terminus

<400>  7

Lys Asp Ser Phe Val Xaa 
1               5       


<210>  8
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa at position 5 is beta Ala

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is Nle with a NH2 group at the carboxy terminus

<400>  8

Asp Ser Phe Val Xaa Leu Xaa 
1               5           


<210>  9
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is beta alanine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Met at position 8 has a NH2 group at the carboxy terminus

<400>  9

Lys Asp Ser Phe Val Xaa Leu Met 
1               5               


<210>  10
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is beta alanine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa at position 8 is Nle with a NH2 group at the carboxy terminus

<400>  10

Lys Asp Ser Phe Val Xaa Leu Xaa 
1               5               


<210>  11
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 can be absent or Lys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa at position 3 can be Ser, Lys, or Arg

<220>
<221>  MISC_FEATURE
<222>  (5)..(6)
<223>  A gamma constrained moiety, 
       (S)-2-((R)-3-amino)-2-oxopyrrolidin-1-yl)-4-methylpantanoyl, is 
       present between Val at position 5 and Xaa at position 6 (Group B)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa at position 6 is either Met-NH2 or Nle-NH2 (Group B)

<400>  11

Xaa Asp Xaa Phe Val Xaa 
1               5       


